Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;34(4):257-262.
doi: 10.1007/s40290-020-00340-1.

Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?

Piotr Nehring  1 , Adam Przybyłkowski  2
Affiliations
Review

Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?

Piotr Nehring et al. Pharmaceut Med. 2020 Aug.

Abstract

Inflammatory bowel diseases-ulcerative colitis and Crohn's disease-are linked with several environmental and genetic risk factors. There are also known drugs able to induce de novo disease or to exacerbate its course. Several autoimmune disorders are more frequent in patients with inflammatory bowel diseases, including psoriasis. The aim of the presented review was to summarise current knowledge on the links between psoriasis therapy and inflammatory bowel diseases. The interleukin-17 inhibitors (secukinumab, brodalumab and ixekizumab) and tumour necrosis factor inhibitor (etanercept), have the potential to induce ulcerative colitis and Crohn's disease de novo or exacerbate existing but silent diseases. There is no evidence that other biologic agents used in psoriasis are lined with such risk. The biologic drugs for psoriasis differ in their potential to induce or worsen inflammatory bowel diseases. Currently, there are no recommendations in European guidelines to screen patients with psoriasis for inflammatory bowel diseases. However, based on available evidence, inflammatory bowel diseases should not be forgotten on in-depth diagnostics in patients with psoriasis.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest related to this article.

References

    1. Maaser C, Langholz E, Gordon H, Burisch J, Ellul P, Ramirez VH, et al. European Crohn's and colitis organisation topical review on environmental factors in IBD. J Crohns Colitis. 2017;11(8):905–920. - PubMed
    1. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014;109(11):1728–1738. - PubMed
    1. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The First European Evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–254. - PMC - PubMed
    1. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110–119. - PubMed
    1. Makredes M, Robinson D, Jr, Bala M, Kimball AB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61(3):405–410. - PubMed

Publication types

MeSH terms